



**Shield Therapeutics plc**  
("Shield" or the "Company" or the "Group")

**Notice of Results**  
*Investor Presentation*

**London, UK, 16 April 2024:** Shield Therapeutics plc (LSE: STX) a commercial-stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anemia), will announce its final results for the year ended 31 December 2023 on Tuesday 30 April 2024.

**Investor presentation**

CEO, Greg Madison, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 14.30 (BST) on Tuesday 30 April 2024.

The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:

<https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor>

Investors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.

**For further information please contact:**

**Shield Therapeutics plc**  
Greg Madison, CEO  
Santosh Shanbhag, CFO

[www.shieldtherapeutics.com](http://www.shieldtherapeutics.com)  
+44 (0) 191 511 8500

**Nominated Adviser and Joint Broker**  
**Peel Hunt LLP**  
James Steel/Patrick Birkholm

+44 (0)20 7418 8900

**Joint Broker**  
**Cavendish Ltd**  
Geoff Nash/George Dollemore/Nigel Birks/  
Harriet Ward

+44 (0)20 7220 0500

**Financial PR & IR Advisor**  
**Walbrook PR**  
Paul McManus/Charlotte Edgar/  
Alice Woodings

+44 (0)20 7933 8780  
[shield@walbrookpr.com](mailto:shield@walbrookpr.com)

**Investor Contact (US Advisor)**  
**LifeSci Advisors, LLC**  
John Mullaly

+1 617 429 3548 or [jmullaly@lifesciadvisors.com](mailto:jmullaly@lifesciadvisors.com)

**About Accrufer®/Feraccru®**  
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: [www.accrufer.com](http://www.accrufer.com) and [www.feraccru.com](http://www.feraccru.com).

**About Shield Therapeutics plc**  
Shield is a commercial stage pharmaceutical company focused on the commercialisation of Accrufer®/Feraccru® (ferric maltol), an innovative oral iron therapy for iron deficiency differentiated from other irons by its efficacy, broad label and well-tolerated formulation. The Group has launched Accrufer® in the US with an exclusive, multi-year collaboration agreement with Viatris, Inc. Feraccru® is commercialised in the UK and European Union by Norgine B.V., that also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s  
Accrufer®/Feraccru® are registered trademarks of the Shield Group

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lse.com](mailto:ms@lse.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORBSGDSBXBDGSU